Predicting neurological Adverse Drug Reactions based on biological, chemical and phenotypic properties of drugs using machine learning models
暂无分享,去创建一个
Salma Jamal | Sukriti Goyal | Asheesh Shanker | Abhinav Grover | S. Jamal | A. Grover | S. Goyal | A. Shanker
[1] R. A. Lucas,et al. Serotonin Syndrome With Standard-Dose Vilazodone (Viibryd ® ) Monotherapy , 2014 .
[2] K. O'brien,et al. Disabling neurological complications of amiodarone. , 1985, Australian and New Zealand journal of medicine.
[3] Nitesh V. Chawla,et al. SMOTE: Synthetic Minority Over-sampling Technique , 2002, J. Artif. Intell. Res..
[4] A. Fliri,et al. Analysis of System Structure–Function Relationships , 2007, ChemMedChem.
[5] Cathy H. Wu,et al. UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..
[6] Roderick E. Hubbard,et al. 3D structure and the drug-discovery process , 2005 .
[7] P. Barach,et al. Clarifying Adverse Drug Events: A Clinician's Guide to Terminology, Documentation, and Reporting , 2004, Annals of Internal Medicine.
[8] D. Ingram,et al. Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice. , 2010, Antiviral research.
[9] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[10] S. Thamarai Selvi,et al. Early Detection of Breast Cancer using SVM Classifier Technique , 2009, ArXiv.
[11] Dragos Horvath,et al. Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.
[12] R. Spector,et al. Serious adverse reactions associated with sulindac. , 1982, Archives of internal medicine.
[13] CHUN WEI YAP,et al. PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..
[14] E. Kurzrock,et al. Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children. , 2004, The Journal of urology.
[15] M. Chandar,et al. Severe Generalized Weakness, Paralysis, and Aphasia following Administration of Irinotecan and Oxaliplatin during FOLFIRINOX Chemotherapy , 2015, Case Reports in Oncology.
[16] L. Cregler. Adverse health consequences of cocaine abuse. , 1989, Journal of the National Medical Association.
[17] Rouslan A. Moro,et al. Support Vector Machines (SVM) as a Technique for Solvency Analysis , 2008 .
[18] C. Miller,et al. Optic-nerve degeneration in Alzheimer's disease. , 1986, The New England journal of medicine.
[19] A. Bénard-Laribière,et al. Severe adverse effects of bromocriptine in lactation inhibition: a pharmacovigilance survey , 2015, BJOG : an international journal of obstetrics and gynaecology.
[20] M. Aapro,et al. Early clinical studies with docetaxel , 1995 .
[21] Rok Blagus,et al. SMOTE for high-dimensional class-imbalanced data , 2013, BMC Bioinformatics.
[22] Ian H. Witten,et al. WEKA - Experiences with a Java Open-Source Project , 2010, J. Mach. Learn. Res..
[23] J. Chen,et al. Predicting adverse side effects of drugs , 2011, BMC Genomics.
[24] R. Girdwood. Abnormalities of Vitamin B12 and Folic Acid Metabolism—their Influence on the Nervous System , 1968, Proceedings of the Nutrition Society.
[25] L. Goldstein,et al. Neuropsychiatric manifestations associated with azithromycin in two brothers , 2010, European Journal of Clinical Pharmacology.
[26] R. Maganti,et al. Neurotoxic effects associated with antibiotic use: management considerations. , 2011, British journal of clinical pharmacology.
[27] F. Vianello,et al. Severe Acute Axonal Neuropathy following Treatment with Arsenic Trioxide for Acute Promyelocytic Leukemia: a Case Report , 2016, Mediterranean journal of hematology and infectious diseases.
[28] Tao Jiang,et al. ChemmineR: a compound mining framework for R , 2008, Bioinform..
[29] V. Parisi. Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer’s disease , 2003, Seminars in ophthalmology.
[30] Muin J. Khoury,et al. Application of support vector machine modeling for prediction of common diseases: the case of diabetes and pre-diabetes , 2010, BMC Medical Informatics Decis. Mak..
[31] Bin Chen,et al. PubChem BioAssays as a data source for predictive models. , 2010, Journal of molecular graphics & modelling.
[32] Dapeng Wu,et al. A RELIEF Based Feature Extraction Algorithm , 2008, SDM.
[33] Corinna Cortes,et al. Support-Vector Networks , 1995, Machine Learning.
[34] A. M. Tomé,et al. Quinolones: review of psychiatric and neurological adverse reactions. , 2011, Drug safety.
[35] Feng Liu,et al. Predicting drug side effects by multi-label learning and ensemble learning , 2015, BMC Bioinformatics.
[36] S. Schroeder,et al. How Many Hours Is Enough? An Old Profession Meets a New Generation , 2004, Annals of Internal Medicine.
[37] W. Bechstein,et al. Neurotoxicity of calcineurin inhibitors: impact and clinical management , 2000, Transplant international : official journal of the European Society for Organ Transplantation.
[38] Hua Xu,et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs , 2012, J. Am. Medical Informatics Assoc..
[39] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[40] Ganesh Bagler,et al. Phenotypic side effects prediction by optimizing correlation with chemical and target profiles of drugs. , 2015, Molecular bioSystems.
[41] R. Pirker,et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. , 1997, European journal of cancer.
[42] M. Aapro,et al. Early clinical studies with docetaxel. Docetaxel Investigators Group. , 1995, European journal of cancer.
[43] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..